Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The Rand Corporation is reporting that, in 2022, employers and private insurers paid hospitals an average 254% more than what Medicare would have spent for the same services in the same facilities.
Around the world, 3 of 4 workers who routinely handle information are now using generative AI on the job. And almost half of them are new to the technology, having begun using it only over the past half-year.
Four of five hospital leaders trust the accuracy of their institution’s data. Yet almost half of useable data gets underutilized if not completely untapped for guiding business and clinical decisions.
Hospital employment models, reimbursement policies and private equity have all led to a massive reduction in the number of cardiologists working for a private practice, ACC President Cathie Biga, MSN, told Cardiovascular Business.
More than two-thirds of U.S. physicians have changed their minds about generative AI over the past year. In doing so, the re-thinkers have raised their level of trust in the technology to help improve healthcare.
Key collaborators across the healthcare AI life cycle now have a common set of principles to which they can hold each other. And that means everyone from developers and researchers to providers, regulators and even patients.
Bumping up hard against the reality of depleted data sources, three of AI’s top players have been acting like they’ve had no choice but to consider cutting corners.
Two-fifths of leaders at academic medical centers, 41%, see reducing average length of patient stay as far and away the No. 1 “most untapped” strategy to turn around falling operating margins.
The agency is urging healthcare providers to transition away from these devices and seek out alternatives. It is even working with other manufacturers to try and get similar products on the market as quickly as possible.
Jeffrey Kuvin, MD, one of the leading voices behind efforts to create a new Board of Cardiovascular Medicine, spoke with Cardiovascular Business about where things stand today.